Nephrology News

A team-based, multicomponent program was linked to risk reductions for several CVD and health outcomes in patients with hypertension when compared with usual care, according to researchers.

The Federal Trade Commission has sued to stop Amgen from acquiring Horizon Therapeutics, a potential blockbuster deal that could restrict marketplace competition, according to an FTC press release.

AUSTIN, Texas — Despite the significant impact that kidney disease and its treatments can have on women’s health, patients admitted knowing very little about it, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.

DESTIN, Fla. — Hydroxychloroquine remains one of the most important drugs in lupus management and should be used as background therapy in nearly all cases, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.

In rheumatology, there is no shortage of conditions that are difficult to diagnose, with diseases like fibromyalgia and systemic lupus erythematosus sometimes taking years before being officially identified — leading to adverse outcomes.

Parathyroidectomy had no significant impact on long-term kidney function among older adults with primary hyperparathyroidism, but if done early, it could preserve function in those aged younger than 60, according to researchers.

Over time, a declining hemoglobin z score correlates with impaired height among children with mild to moderate nonglomerular chronic kidney disease, according to data published in the American Journal of Kidney Diseases.

The Health Resources Services Administration, which oversees the contract with the United Network for Organ Sharing to manage the U.S. organ procurement system, has launched a new initiative aimed at improving access to donor organs.

The incidence of kidney stone recurrence did not significantly differ among patients who received hydrochlorothiazide compared with those who received placebo, according to a study published in The New England Journal of Medicine.